Overcoming Primary Resistance to Checkpoint Inhibitors: Update on Clinical Trials of IFx-Hu2.0 in MCC
TuHURA Biosciences, Inc. is initiating a Phase 1b/2a trial of IFx-Hu2.0 in combination with pembrolizumab(Keytruda, Merck) when administered via Interventional Radiology (IR) in metastatic Merkel Cell carcinoma of unknown primary origin (MCCUP).